<DOC>
	<DOC>NCT00641160</DOC>
	<brief_summary>The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for which there are no currently accepted therapies.</brief_summary>
	<brief_title>Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>capable of understanding study requirements and able to provide Informed Consent diagnosed with a nonhematologic malignancy for which there are no currently accepted therapies life expectancy at least 3 months agreement to use medically acceptable contraception throughout the study willing and able to comply with the protocol requirements currently receiving systemic treatment for malignancy not yet recovered from the toxicity of prior therapies platelet count &lt; 100,000 cells/mm3 within 7 days prior to study entry ANC &lt; 1500 cells/mm3 within 7 days prior to study entry hemoglobin &lt; 8.5 g/dL within 7 days prior to study entry AST and/or ALT &gt; 2.5 X ULN within 7 days prior to study entry total bilirubin &gt; 1.5 X ULN within 7 days prior to study entry creatinine clearance &lt; 60 mL/min (CockroftGault formula) within 7 days prior to study entry receipt of any investigational therapy within 3 weeks prior to study entry known history of HIV, HBV, and/or HCV infection clinically relevant active infection or serious comorbid medical condition at study entry major surgery within 4 weeks prior to study entry other malignancy within 3 year prior to study entry pregnant or breastfeeding presence of a concomitant disease or condition which, in the opinion of the Investigator, could interfere with the conduct of the study or could put the subject at unacceptable risk</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>vinorelbine</keyword>
	<keyword>metronomic dosing</keyword>
	<keyword>oral administration</keyword>
	<keyword>nonhematologic malignancies</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>